Do Wall Street Analysts Like AbbVie Stock?

North Chicago, Illinois-based AbbVie Inc. (ABBV) is a research-based biopharmaceutical company with a market cap of $385.2 billion. It discovers, develops, manufactures and commercializes innovative medicines that address complex health challenges across therapeutic areas such as immunology, oncology, neuroscience, eye care and aesthetics. 

Shares of this healthcare company have lagged behind the broader market over the past 52 weeks. AbbVie has gained 6.6% over this time frame, while the broader S&P 500 Index ($SPX) has soared 17.7%. Nonetheless, on a YTD basis, the stock is up 22.1%, outpacing SPX’s 16.3% uptick.